Vitality Biopharma (OTCQB:VBIO) announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.
As quoted in the press release:

The publication of the international patent filing is the first public disclosure of its full content, which includes 79 patent claims and almost 200 individual compounds. Novel cannabinoid prodrugs are described for the most common phytocannabinoids, THC, cannabidiol (CBD), and CBDV, as well as a variety of other phytocannabinoids and endocannabinoids. The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide. Coverage of any underlying patent claims would extend to 2035 in the United States, and may be subject to patent term extensions that would extend this patent protection. The full text may be accessed online: “https://patentscope.wipo.int/search/docservicepdf_pct/id00000037217335/PDOC/WO2017053574.pdf“.
In addition, the Company has filed for intellectual property coverage for methods to treat dysbiosis, gastrointestinal infections, and other digestive disorders using cannabinoids. The Company’s prodrug technology enables large concentrations of cannabinoids to be selectively delivered to the intestinal tract and avoids psychoactivity, making them well suited for treatment of pediatric conditions.


Click here to read the full press release.

Source: www.marketwired.com

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less